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Abstract
Glioma is the most frequent primary brain tumor of adults that has a presumably glial origin. Although our knowledge
regarding molecular mechanisms and signaling pathways involved in gliomagenesis has increased immensely during the past
decade, high-grade glioma remains a lethal disease with dismal prognosis. The failure of current therapies has to a large extent
been ascribed the functional heterogeneity of glioma cells. One reason for this heterogeneity is most certainly the large number
of variations in genetic alterations that can be found in high-grade gliomas. Another factor that may inﬂuence glioma
heterogeneity could be the cell type from which the glioma is initiated. The cell of origin for glioma is still undeﬁned, and
additional knowledge about this issue may prove critical for a more complete understanding of glioma biology. Based on
information from patients, developmental biology, and experimental glioma models, the most putative target cells include
astrocytes, neural stem cells, and oligodendrocyte precursor cells, which are all discussed in more detail in this article. Animal
modeling of glioma suggests that these three cell types have the capability to be the origin of glioma, and we have reason to
believe that, depending on the initiating cell type, prognosis and response to therapy may be signiﬁcantly different. Thus, it is
essential to explore further the role of cellular origin in glioma.
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Histopathological and molecular classiﬁcation
of glioma
Glioma is the most common primary intracranial
tumor with a worldwide incidence of approximately
7 out of 100,000 individuals per year. Despite exten-
sive efforts and huge progress in our knowledge about
the underlying mechanisms of glioma development
during the last decades, there is still no cure, and the
median survival for patients diagnosed with the most
frequent and malignant form of glioma, glioblastoma
(GBM), remains at 12–15 months (1).
Gliomas are graded from I to IV according to the
World Health Organization (WHO) malignancy
scale. Grade I lesions are benign and relatively cir-
cumscribed with a slow proliferation rate and include
the most common glioma of children, pilocytic astro-
cytoma. Grade II tumors, including astrocytoma,
oligodendroglioma, and oligoastrocytoma, also have
a slow growth rate and a high degree of cellular
differentiation, but unlike pilocytic astrocytomas
these tumors grow diffusely into the normal brain
parenchyma and are prone to malignant progression.
Grade III tumors include anaplastic astrocytoma,
anaplastic oligodendroglioma, and anaplastic oligoas-
trocytoma, which are characterized by a higher cellu-
lar density and the ample existence of atypia and
mitotic cells. Grade IV tumors are the most malignant
and also the most frequent gliomas and include glio-
blastoma and gliosarcoma. These tumors display, in
addition to grade III features, either or both of the
hallmarks of grade IV glioma: microvascular prolif-
erations and pseudopalisading necrosis.
Large-scale genomic analyses of human glioblastoma
have identiﬁed numerous mutated genes, and the data
propose that three core signaling pathways are altered in
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DOI: 10.3109/03009734.2012.658976the majority of the tumors: the receptor tyrosine kinase
(RTK)/RAS/PI3K pathway, where EGFR ampliﬁca-
tion, PDGFRA overexpression or ampliﬁcation, and
PTEN inactivation are among the most common muta-
tions; the p53 pathway, where inactivation of p53 and
p14
Arf are key events; and the RB pathway, with inac-
tivation of RB and p16
Ink4a as the most frequent altera-
tions (1,2). In addition, when the large-scale genomics
data were combined with large-scale gene expression
and proteome analyses of glioblastomas, that by mere
histopathology were inseparable, a classiﬁcation based
on the tumors’ molecular proﬁles into 3–4s u b t y p e s
could be generated (3-5).
High-grade gliomas display a large degree of het-
erogeneity, both among tumors with the same diag-
nosis and among tumor cells within the same tumor.
This morphological, cellular, and molecular hetero-
geneity is probably to a large extent caused by varia-
tions in the combinations of genetic and epigenetic
mutations that have occurred during glioma develop-
ment. As mentioned above, we now have substantial
knowledge regarding this aspect of glioma. An addi-
tional contributor to glioma heterogeneity could be
the cell type from which the glioma originates, which
is still undeﬁned. This aspect has been investigated
using various mouse models of glioma (Table I), but
transfer of that knowledge to human glioma has not
been convincingly done. Recent ﬁndings that com-
mitted glial cells have the potential to be the cell of
origin for glioma (6-8) have renewed the attention on
the glioma cell of origin. We believe that to truly
understand the complex biology of gliomas it is
essential to know both the genetic alterations of
that tumor and from which cell type it has arisen,
information that could build the foundation for
designing new, more efﬁcient, and more speciﬁc
treatment strategies. Below we will discuss the most
studied candidate cells of origin for glioma, namely
the astrocyte, the neural stem cell (NSC), and the
oligodendrocyte precursor cell (OPC).
Relationship between cell of origin, cell of
mutation, and glioma-derived cancer stem
cells
There are histopathological similarities between glio-
mas and normal glial cells of the brain, as evidenced
by immunostainings showing glial tumors to express
numerous glial markers. This was the basis for the
assumption made almost a century ago that gliomas
would originate from a glial cell type. Many years
later, with the discovery of glial stem and progenitor
cells (9-12), the interest was further narrowed to
immature glial cells. The fairly recent identiﬁcation
of glioma-derived cancer stem cells or glioma-
initiating cells (GICs) in high-grade gliomas (13–15)
was interpreted as a further support for an immature
cell as the origin of glioma, since GICs were shown to
exhibit many of the same properties as NSCs such as
expression of NSC markers, the ability of extended
self-renewal, and the capacity to differentiate into cells
expressing glial and neuronal markers. These cells are
thought to sustain tumor development, and they have
been shown to resist radiotherapy (16) and chemo-
therapy (17), making them a vital target for drug
development. However, when during tumor develop-
ment, and how, GICs occur is still unknown. Very
recently an additional complexity to this matter was
discovered when it was shown in an experimental
model of glioma that the cell of mutation and the
cell of origin could be different cell types (7). When
p53 and NF1 were homozygously mutated in NSCs
using the MADM (mosaic analysis with double mar-
kers) mouse model, malignant transformation gener-
ating gliomas occurred only in OPCs. Whether this
means that OPCs in general are more susceptible to
oncogenic transformation than other glial cell types, or
if OPCs are more susceptible to this particular com-
bination of genetic alterations is yet to be determined.
Mouse models to study origin of glioma
At the time of diagnosis the majority of glioma
patients are already in a late stage of the disease,
which makes it unfeasible to study the cell of origin
in humans. To address this issue, results from genet-
ically modiﬁed mouse models can be used (Table I).
In many (but not all) instances these models were
initially made with the intention to study the causal
effects of speciﬁc genetic mutations commonly found
in human glioma. To establish models that would be
relevant to human glioma various neural and glial
promoters have been utilized to direct the genetic
lesions to glial cells, which has generated information
also about the putative cellular origin of these tumors.
The models can be divided into two categories: germ-
line modiﬁcation models and somatic cell gene trans-
fer models.
In germline modiﬁcation models gliomas are gen-
erated by depletion of tumor suppressor genes or
overexpression of oncogenes, traits that are inherited
in a Mendelian pattern. By using cell type-
speciﬁc promoters, genetic modiﬁcations can be
directed to speciﬁc neural and glial cell lineages.
The application of the Cre/loxP technology further
allows the genetic alterations to happen at a speciﬁc
time in development and/or in a speciﬁed region or
cell type (18). Recently, as already mentioned, the
MADM-based model was used to study glioma devel-
opment, which allowed lineage tracing to follow the
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premalignant cell of mutation and the malignant cell
of origin (7).
In somatic cell gene transfer models the genetic
alterations are delivered to speciﬁc somatic cell types
by retroviral infection. Stable integration of the ret-
roviral genome into the host cell genome followed by
expression of virally transduced genes can cause cell
transformation and tumor development. To obtain
cell type speciﬁc retroviral infection the RCAS (rep-
lication competent ALV splice acceptor)/tv-a system
has been extensively used to study glioma develop-
ment (19). RCAS is derived from the avian sarcoma-
leukosis virus family, and its receptor, tv-a, is not
present in the mammalian genome. RCAS virus
can be manipulated to express a gene of choice,
propagated in cultured chicken cells, and injected
into tv-a transgenic mice where it will infect dividing
cells. Several mouse lines have been generated that
express tv-a under the control of glial-speciﬁc pro-
moters (8,20,21), which allows for targeted infection
by RCAS through stereotactic injections to a deﬁned
location of the brain and at a speciﬁed time in devel-
opment (22). The tv-a mouse lines have been crossed
with mice deﬁcient for tumor suppressor genes, e.g.
Ink4a, Arf, or combined loss of both (Cdkn2a), to
investigate how combinations of mutations affect gli-
oma development (23). Also a lentivirus-based glioma
model has been developed recently where lentiviral
vectors containing activated oncogenes ﬂanked by
loxP sites were injected into GFAP-Cre transgenic
mouse brains (24).
Astrocytes as putative cell of origin for glioma
For a long time, before the discovery of adult NSCs,
astrocytes were thought to be the only dividing cells in
the adult brain (25). That, together with the fact that
the astrocytic marker GFAP could be frequently
found in human glioma tissue, made astrocytes a valid
candidate to be the cell of origin for glioma (26). One
concern with this hypothesis has been that it presumes
that dedifferentiation should take place to give rise to
the seemingly more immature cells present in high-
grade glioma. Evidence that astrocytes could hold the
capacity to dedifferentiate has been produced by
several labs. Long-time exposure of mature astrocytes
to TGF converted the cells ﬁrst to radial glial cells and
later to neural stem cell-like cells (27). When these
dedifferentiated astrocytes were exposed to gamma
radiation, they became immortalized and could
induce high-grade gliomas after brain engrafting
(28). Further, primary astrocytes obtained from new-
born Ink4a/Arf
-/- mice that were cultured in serum-
free media supplemented with EGF underwent a
rapid change in morphology and after 10 days started
to form neurospheres that demonstrated a complete
loss of GFAP but expressed nestin and A2B5 (29).
These cells were shown to be equally as sensitive as
NSCs to transformation with a mutated epidermal
growth factor receptor (EGFR), and orthotopic trans-
plantation of transduced cells to mice caused devel-
opment of high-grade gliomas.
To analyze the potential of astrocytes to act as cell
of origin in mouse glioma models, the GFAP
Table I. Mouse models with conﬁrmed or candidate cell of origin for glioma.
Cell of origin Promoter Deleted or inactivated genes
Overexpressed or
activated genes Ref
Astrocyte NA p16
Ink4a and p19
Arf Mutant EGFR (29)
GFAP v-Src (30)
GFAP Ha-Ras (31)
GFAP pRb, p107, p130 (32)
GFAP (RCAS-tv-a) PDGF-B (21)
Neural stem or
progenitor cell
Nestin-CreERT2 Nf1, p53, and/or Pten (63)
GFAP-Cre H-Ras and Akt (24)
Nestin (RCAS-tv-a) K-Ras and Akt (64)
NA p16
Ink4a and p19
Arf Mutant EGFR (29)
Oligodendrocyte
precursor cell
NA p53 Ras (74)
CNP (RCAS-tv-a) PDGF-B (8)
S100b Mutant EGFR (6)
GFAP-Cre or Nestin-Cre Nf1 and p53 (7)
NA = not applicable.
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sion of many different oncogenic mutations. Some
examples are: 1) Expression of a constitutively acti-
vated tyrosine kinase v-src in GFAP-expressing cells
was shown to induce astrocytomas with a less than
20% penetrance (30). 2) Expression of an activated
form of H-Ras in astrocytes led to astrocytoma for-
mation in over 95% of the mice, and there was a dose-
dependent correlation between Ras expression and
tumor grade (31). 3) Inactivation of pRb, p107, and
p130 by a truncated SV40 T-antigen (T121)i n
GFAP-expressing cells induced astrocytomas in
100% of the mice, and the process was accelerated
by heterozygous loss of PTEN (32). 4) Somatic deliv-
ery of PDGF-B to astrocytes of newborn mice using
the RCAS/tv-a system resulted in oligodendrogliomas
or mixed oligoastrocytomas in about 40% of the mice
by the age of 12 weeks (21). In all these studies the
GFAP promoter was used, and astrocytes were the
assumed target cells. However, there is a possibility
that the tumors could have originated from other cell
types since GFAP is also expressed by radial glial cells
(33) and NSCs of the adult subventricular zone (34).
The potential of the NSC as origin for glioma
The NSC of the subventricular zone (SVZ) has been a
candidate cell of origin for glioma for many decades.
Early observations from patients showed that human
brain tumors were frequently located near the SVZ,
suggesting that they had originated from the
‘subependymal plate’ (35), a notion that was recently
corroborated in a large series of patients which
showed that 93% of cases contacted the lateral ven-
tricular wall (36). A series of studies performed in the
1960s and 1970s showed that an area adjacent to the
cerebral ventricles was more sensitive than the rest of
the brain to chemical and virus-induced gliomagen-
esis (37,38). This was the same region that in rodents
and primates had been found to contain cells with
mitotic activity regarded as NSCs (39,40). The true
identiﬁcation of a bona ﬁde adult NSC was ﬁrst made
in the mouse in the 1990s, followed by similar ﬁnd-
ings in other species, such as monkey and human
(9-11,41). These ﬁndings established that adult NSCs
were mainly located in the SVZ ofthelateral ventricles
and in the dentate gyrus of the hippocampus. These
NSCs have been shown to express several cell surface
markers such as nestin (10), Sox2 (42), CD133 (43),
and GFAP including GFAP delta (9,44), but none of
these markers is unique to NSCs.
Another indication that NSCs could be the cell of
origin for glioma is that signaling pathways, which
are important for regulating self-renewal, prolifer-
ation, and differentiation of NSCs, are commonly
a l t e r e di ng l i o m a s .T h er o l eo fe p i d e r m a lg r o w t h
factor receptor (EGFR) signaling has been widely
studied in both NSCs and glioma development.
During rat brain development, EGF expression
can be detected as early as on embryonic day
14 and remains detectable in the adult brain-
stem, cerebellum, hippocampus, diencephalon,
and telencephalon (45). EGFR signaling can induce
proliferation of a small cluster of cells isolated from
the adult mouse striatum, and these cells exhibit
properties of NSCs (10). EGFR signaling can also
regulate the fate decision of neural stem/
progenitor cells and thus contribute to adult neu-
rogenesis (46). The EGFR gene is mutated or
ampliﬁed in 45% of glioblastomas (2). The most
common mutation is EGFRvIII, which has a dele-
tion of exons 2–7 generating a ligand-independent,
constitutively activated extracellular domain
(47-49). Another example is PTEN, a protein tyro-
sine phosphatase that negatively regulates the AKT/
PKB signaling pathway. PTEN can suppress pro-
liferation of NSCs, and mice deﬁcient for PTEN
have enlarged and abnormally structured brains
(50). PTEN is mutated or homozygously deleted
in 36% of glioblastomas (2). BMI-1, a member of
the polycomb group of transcriptional repressors
regulating expression of the CDKN2a locus, is a
third example. BMI-l depletion in mice results in
postnatal growth retardation and neurological
defects (51) due to reduced self-renewal capacity
of BMI-1-deﬁcient NSCs (52). BMI-1 copy num-
ber variations have been observed in a subset of
gliomas (53), and targeting BMI-1 by microRNA-
128 could inhibit glioma proliferation (54). A fourth
example is secreted signals, such as Notch and Wnt,
which have been extensively studied in normal neu-
ral development. Notch acts as a key regulator of
plasticity in the brain, balancing the number of
NSCs and their progenies to maintain the stem
cell niche, by regulating the cell cycle (55,56).
Notch-1 and its ligands, Delta-like-1 and Jagged-1,
have been shown to be overexpressed by many
glioma cell lines (57). Moreover, merely interfering
with either Notch-1 or its ligands can induce apo-
ptosis and inhibit proliferation in a number of gli-
oma cell lines. Wnt is necessary for the development
of the midbrain and rostral metencephalon in
the mouse (58). A recent study showed that Wnt
signaling was absent when neural stem cells were
dividing asymmetrically and was up-regulated upon
symmetrical division. Thus, Wnt signaling could
regulate the size of the stem cell pool (59). Although
aberrant Wnt signaling is more common in a subset
of medulloblastomas, and mutations of Wnt path-
way genes are rare in gliomas, a close correlation of
116 Y. Jiang & L. Uhrbomthe Wnt/-catenin pathway with glioma progression
has recently been found (60).
A third line of support for the NSC as a potential
cellular origin for glioma comes from mouse models.
Mice carrying combined germline mutation of p53
and conditional knock-out of Nf1 developed a spec-
trum of astrocytomas with 100% penetrance (61).
Histopathology analysis of these tumors demon-
strated that presymptomatic lesions were located
within the SVZ, suggesting that SVZ stem cells
may serve as cells of origin. Additional mutations
of one or both alleles of Pten enabled tumor progres-
sion to anaplastic astrocytomas or glioblastoma (62).
In this model, ectopic migration of Nf1;p53;Pten-
deﬁcient neural stem/progenitor lineage cells could
be observed. Further studies from the same group
proved that the inactivation of p53, Nf1,o rPten in
adult neural stem/progenitor cells was sufﬁcient to
induce astrocytoma formation (63). In contrast, the
same combination of mutations in non-neurogenic
regions of adult mice did not result in tumor forma-
tion. A similar study whereby H-RAS and AKT were
activated in GFAP + cells of the hippocampus, the
SVZ or the cortex of adult mice heterozygous for p53
showed that glioblastomas could only robustly
develop when transformation happened in the ﬁrst
two areas (24). This observation was consistent with
previous studies performed in newborn mice where
Nestin + neural stem/progenitor cells were shown to
be more sensitive to K-RAS and AKT transformation
than GFAP + astrocytes (64). However, as already
discussed, nestin and GFAP promoters are not
unique to NSCs, since Nestin is expressed also by
glial progenitor cells and astrocytes, and GFAP is
additionally expressed by radial glial cells and
astrocytes.
An alternative in vivo strategy to determine the
potential of a cell type to be the cellular origin of
glioma is to manipulate cells in vitro followed by
transplantation to mice. NSC cultures have been
established from Ink4a/Arf
-/- mice that were trans-
duced with retrovirus encoding a mutated form
of the EGFR. These cells could induce high-
grade gliomas when orthotopically transplanted
into the brains of SCID mice (29). Another study
using human NSC cultures established from glioma
samples demonstrated that after 30 passages, when
most cells had entered senescence, a spontaneous
immortalized NSC clone emerged. This clone
exhibited the characteristics of GICs, such as exten-
sive self-renewal and high in vivo tumorigenicity
(65). However, it should be noted that in vitro
culture conditions are very different from the
in vivo microenvironment and may cause a clonal
selection of non-representative cells.
Strong experimental support for the OPC
as cell of origin for glioma
The OPC, marked by expression of e.g. NG2 (66),
PDGFR (67), A2B5 (68), and CNPase (69), is the
major dividing cell population in the adult brain and
gives rise to oligodendrocytes. The broad distribution
of OPCs in the SVZ, white matter, and gray matter,
together with their proliferative ability, makes them a
susceptible target to oncogenic transformation. In
support of this, the PDGFRa signaling pathway
involved in normal development of oligodendrocytes
by controlling proliferation and migration of OPCs
(70) is also commonly altered in gliomas (1,2). Also
markers connected with OPCs, such as NG2 and
PDGFR, have been found readily expressed in oligo-
dendrogliomas, pilocytic astrocytomas, and glioblas-
tomas (71). Further, integrated genomic analysis
revealed that alteration of PDGFR was a key feature
of the proneural subtype of glioblastomas (4).
OPCs were, for many years, regarded as irreversibly
committed precursor cells that could only give rise to
oligodendrocytes in vivo and oligodendrocytes and
type-2 astrocytes in culture (72). Now we know that
OPCs are more plastic and can be converted to
immature multipotent cells in vitro that in turn can
give rise to neurons, type-1 astrocytes, and oligoden-
drocytes (73). Further, it has been shown that OPCs
can be transformed to GIC-like cells by a combination
of Ras activation and p53 depletion, and these cells
were highly efﬁcient in inducing secondary tumors
(74). Interestingly, the gene expression proﬁle of the
transformed OPCs showed that these cells had under-
gone global reprogramming and were more similar to
NSCs than OPCs.
More solid evidence pointing to OPCs as cell of
origin in glioma has emerged in recent years. In our
laboratory we had observed that the majority of gli-
omas induced in Ntv-a and Gtv-a mice had expres-
sion of NG2 in their tumors. This was true for both
combined AKT + KRAS (75) and PDGF-B (23)
induced tumors, and, in addition, tumor cells had
often lost their expression of nestin or GFAP. We
reasoned that the oncogenic signaling somehow could
drive the tumor cells into an ‘optimal state of
differentiation’ for tumor development to occur,
and based on the NG2 positivity that state was puta-
tively an OPC. To analyze if OPCs could serve as cell
of origin for glioma we developed a new tv-a trans-
genic mouse line, Ctv-a, in which viral infection could
be targeted to OPCs expressing 2’,3 ’-cyclic nucleo-
tide 3’-phosphodiesterase (CNP). CNP is a highly
speciﬁc marker that in the central nervous system is
only expressed late in OPC development and in
mature oligodendrocytes. In the Ctv-a mouse we
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RCAS-PDGF-B. Although the cells that were
infected were CNP+, the tumor cells were always
CNP- but expressed other earlier OPC markers
such as SOX2, SOX10, OLIG2, NG2, and PDGFR,
which we interpreted as a slight dedifferentiation of
tumor cells (8). Subsequently, corroborating our ﬁnd-
ing that OPCs could serve as cell of origin, gliomas
generated in the S100b-vErb transgenic mouse model
were deduced to have an OPC origin based on devel-
opmental and gene expression studies (6). In a very
recent study using the MADM-based lineage tracing
model to mutate sporadically p53/Nf1 in NSCs, aber-
rant growth of pre-tumor lesions could only be found
in cells that had differentiated along the oligodendro-
cyte lineage to become OPCs, and not in any of the
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Figure 1. Putative glioma cell of origin and its role for glioma development. A: A simpliﬁed schematic representation of glial cell development
from the multipotent CNS stem cell into astrocytes and oligodendrocytes, where each stage is deﬁned by the expression of markers. Red
lightings indicate the occurrence of an oncogenic event that will induce glioma development. B: The role of cellular origin for glioma initiation,
progression, recurrence and response to therapy remains largely unknown. The search for biomarkers that could distinguish phenotypically
distinct glioma subgroups based on cell of origin could be one path towards elucidating this matter. NSC = neural stem cell; GRPC = glial
restricted progenitor cell; APC = astrocyte precursor cell; OPC = oligodendrocyte precursor cell.
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(7). As a proof of concept, OPCs could also be
directly transformed by p53/Nf1 mutations in vitro,
and the induced gliomas were indistinguishable from
those initiated in NSCs. This is the ﬁrst study to show
that the cell of mutation and the cell of origin could be
distinct cells, and further support the potential of
OPCs to be the cell of origin for glioma. Due to
the lack of unique markers for NSCs and astrocytes
we argue that until now the most solid data from
mouse modeling come from the OPC studies. The
CNP promoter is highly speciﬁc to OPCs, and many
of the other markers (e.g. NG2 and PDGFR) that
were used to conﬁrm the OPC origin in these studies
(6–8) also have a narrow and rather speciﬁc expres-
sion pattern.
Conclusion and perspective
The cell of origin for glioma remains unresolved, but
experimental in vivo data show that many cell types of
the brain may be capable of being that cell (Figure 1A).
This suggests that human glioma can develop from
many different cell types, and if adding to that the large
collection of genetic alterations that have been identi-
ﬁed in these tumors the complexity of glioma biology
becomes apparent. We think that it could prove essen-
tial to take into account the dimension of cellular
origin, since most likely this will give a more accurate
representation of the properties of a particular glioma
and thereby a better prediction of how the patient will
respond to different therapeutic strategies. Therefore,
it is important to continue to study the cell of origin for
glioma, to investigate how the originating cell type
affects glioma initiation, progression, recurrence, and
response to therapy, and to identify biomarkers differ-
entiating cellular origin that could be of predictive and
therapeutic importance (Figure 1B).
Several strategies could be applied to explore cel-
lular origin. Mouse models are powerful tools to study
human disease. More cell type speciﬁc promoters are
needed to be able to drive the initial oncogenic event
within a well-deﬁned cell population along the glial
development axis. Optimal promoter candidates
should have a narrow expression window during
normal glial development. E.g. by combining the
MADM-based lineage tracing method with other
promoters and additional genetic mutations, conse-
quences of novel combinations of genetic events and
cell of origin could be analyzed in vivo.
Another path could be to use cross-species geno-
mics. This is a strategy that has been successfully used
to identify the cell of origin for speciﬁc subtypes of
human medulloblastoma and ependymoma (76). In
these studies the global gene expression proﬁles of
deﬁned populations of normal mouse cells, from
different stages of development and speciﬁed loca-
tions of the brain, were compared to the proﬁles of
different subtypes of human brain tumors. We suggest
using this method in a slightly different way to com-
pare gene expression proﬁles of mouse GICs derived
from different and speciﬁed cellular origin to a large
set of human GICs, with the aim to identify subclasses
of human gliomas based on cellular origin. Our group
has established GICs from experimentally induced
mouse glioblastoma-like tumors with deﬁned cellular
origin, and we have found intriguing phenotypic
differences of the GICs despite the fact that they
have all been derived from grade IV tumors and are
driven by the same initiating event (Y.J. and L.U.,
unpublished data). Global gene expression analysis is
underway with the aim to stratify patient-
derived GICs and to identify predicative and thera-
peutic biomarkers that are greatly needed for this
incurable disease.
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